Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease that is chronic and progressive and is characterized by an excessive buildup of fibrotic tissue in the lungs. Antifibrotic therapy, which tries to decrease disease development and enhance patient outcomes, is the main emphasis of IPF care. Current information on the use of antifibrotic medications in the treatment of IPF is included in this review. The fibrosis, inflammation, and remodeling processes in IPF are the targets of the mechanisms of action of antifibrotic medications such pirfenidone and nintedanib. These medications have been shown to be effective and safe in clinical studies and in real-world settings, and there is evidence that they can delay the progression of illness, maintain lung function, and enhance quality of life. Long-term outcomes, such as survival and a reduction in lung function, are crucial markers of therapeutic success. Antifibrotic medications combined with other substances, such as immunomodulators and antioxidants, have the potential to improve treatment outcomes. Future research in antifibrotic therapy for IPF will focus on discovering new therapeutic targets, individualized treatment plans, and potential biomarkers for tracking and predicting the progression of the condition. This review emphasizes the need for additional study to enhance IPF management approaches and enhance patient outcomes. Overall, antifibrotic medications are essential in the treatment of IPF, and further research in this area has the potential to benefit IPF patients' quality of life.